📊 TGTX Key Takeaways
Is Tg Therapeutics, Inc.. (TGTX) a Good Investment?
Strong revenue growth of 87.3% YoY and healthy balance sheet metrics are overshadowed by a critical disconnect between reported net income of $447.2M and negative operating cash flow of -$24.8M, indicating profits are driven by one-time, non-cash gains rather than sustainable operations. The 72.6% net margin is unrealistically high for pharmaceuticals, raising significant earnings quality concerns.
Why Buy Tg Therapeutics, Inc.. Stock? TGTX Key Strengths
- Strong 87.3% YoY revenue growth demonstrates market expansion
- Excellent liquidity position with 4.1x current ratio and 3.29x quick ratio
- Conservative leverage with 0.38x debt-to-equity ratio and exceptional 53.9x interest coverage
TGTX Stock Risks: Tg Therapeutics, Inc.. Investment Risks
- Critical disconnect: $447.2M net income with -$24.8M operating cash flow indicates one-time non-recurring gains driving profits
- 72.6% net margin is unrealistically high for pharmaceutical sector, suggesting one-time events or accounting anomalies
- Negative free cash flow of -$25.0M despite massive reported profitability raises sustainability and earnings quality concerns
Key Metrics to Watch
- Operating cash flow reconciliation with net income to identify one-time vs. recurring items
- Normalized net margin excluding one-time gains
- Free cash flow generation in subsequent quarters
Tg Therapeutics, Inc.. (TGTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.10x current ratio provides a solid financial cushion.
TGTX Profit Margin, ROE & Profitability Analysis
TGTX vs Healthcare Sector: How Tg Therapeutics, Inc.. Compares
How Tg Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tg Therapeutics, Inc.. Stock Overvalued? TGTX Valuation Analysis 2026
Based on fundamental analysis, Tg Therapeutics, Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tg Therapeutics, Inc.. Balance Sheet: TGTX Debt, Cash & Liquidity
TGTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tg Therapeutics, Inc..'s revenue has grown significantly by 164% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.09 reflects profitable operations.
TGTX Revenue Growth, EPS Growth & YoY Performance
TGTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $83.9M | $52.0K | $0.00 |
| Q2 2025 | $73.5M | -$3.8M | $-0.03 |
| Q1 2025 | $63.5M | $5.1M | $0.03 |
| Q3 2024 | $83.9M | $52.0K | $0.00 |
| Q2 2024 | $16.1M | -$3.8M | $-0.03 |
| Q1 2024 | $7.8M | -$10.7M | N/A |
| Q3 2023 | $94.0K | $27.1M | $0.19 |
| Q2 2023 | $594.0K | N/A | $-0.30 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tg Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
TGTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tg Therapeutics, Inc.. (CIK: 0001001316)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TGTX
What is the AI rating for TGTX?
Tg Therapeutics, Inc.. (TGTX) has an AI rating of HOLD with 58% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TGTX's key strengths?
Claude: Strong 87.3% YoY revenue growth demonstrates market expansion. Excellent liquidity position with 4.1x current ratio and 3.29x quick ratio.
What are the risks of investing in TGTX?
Claude: Critical disconnect: $447.2M net income with -$24.8M operating cash flow indicates one-time non-recurring gains driving profits. 72.6% net margin is unrealistically high for pharmaceutical sector, suggesting one-time events or accounting anomalies.
What is TGTX's revenue and growth?
Tg Therapeutics, Inc.. reported revenue of $616.3M.
Does TGTX pay dividends?
Tg Therapeutics, Inc.. does not currently pay dividends.
Where can I find TGTX SEC filings?
Official SEC filings for Tg Therapeutics, Inc.. (CIK: 0001001316) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TGTX's EPS?
Tg Therapeutics, Inc.. has a diluted EPS of $2.77.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TGTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Tg Therapeutics, Inc.. has a HOLD rating with 58% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TGTX stock overvalued or undervalued?
Valuation metrics for TGTX: ROE of 69.0% (sector avg: 15%), net margin of 72.6% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy TGTX stock in 2026?
Our dual AI analysis gives Tg Therapeutics, Inc.. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is TGTX's free cash flow?
Tg Therapeutics, Inc..'s operating cash flow is $-24.8M, with capital expenditures of $214.0K. FCF margin is -4.1%.
How does TGTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 72.6% (avg: 12%), ROE 69.0% (avg: 15%), current ratio 4.10 (avg: 2).
Why is TGTX's return on equity (ROE) so high?
Tg Therapeutics, Inc.. has a return on equity of 69.0%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 72.6% net margin.